Grenoble, France-based UroMems — which has its U.S. headquarters in Minneapolis — develops an implantable system called UroActive. Powered by a MyoElectroMechanical system (MEMS), UroActive goes into the urethral duct in men and bladder neck in women. It’s controlled by a patient’s activity without the need for manual adjustments. This provides patients ease of use and better quality of life compared to other options.

The company previously had positive early feasibility data in a study of six men, then reported the first-ever female implant last year. In June 2024, the company raised $47 million to support clinical trials for its smart automated artificial urinary sphincter (AUS).